Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Short Interest Up 88.7% in July

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was the recipient of a significant growth in short interest in the month of July. As of July 15th, there was short interest totaling 268,144 shares, a growth of 88.7% from the June 30th total of 142,122 shares. Based on an average daily trading volume, of 1,758,154 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.0% of the company’s shares are short sold.

Bayer Aktiengesellschaft Stock Down 0.6%

OTCMKTS:BAYRY opened at $13.89 on Friday. Bayer Aktiengesellschaft has a 1 year low of $7.19 and a 1 year high of $15.23. The stock has a 50-day moving average price of $12.32 and a two-hundred day moving average price of $12.06. The stock has a market cap of $54.59 billion, a price-to-earnings ratio of -21.70, a PEG ratio of 4.48 and a beta of 0.55. The company has a current ratio of 1.05, a quick ratio of 0.70 and a debt-to-equity ratio of 1.06.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last released its quarterly earnings results on Tuesday, May 12th. The company reported $0.79 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.15. Bayer Aktiengesellschaft had a positive return on equity of 17.61% and a negative net margin of 4.75%.The company had revenue of $15.73 billion for the quarter, compared to analyst estimates of $15.77 billion. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. As a group, equities analysts expect that Bayer Aktiengesellschaft will post 1.25 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Deutsche Bank Aktiengesellschaft raised Bayer Aktiengesellschaft from a “hold” rating to a “buy” rating in a research note on Thursday, July 2nd. Jefferies Financial Group upgraded shares of Bayer Aktiengesellschaft to a “hold” rating in a report on Friday, May 29th. Zacks Research raised shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 10th. Finally, DZ Bank upgraded shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 19th. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, Bayer Aktiengesellschaft presently has an average rating of “Buy”.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.